Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Dengvaxia
Synonyms :
dengue vaccine
Class :
Vaccines
Brand Name :
Dengvaxia
Synonyms :
dengue vaccine
Class :
Vaccines
See Pediatric Dosing
Dosage Forms & Strengths Â
Powder for injection Â
4.5-6 log10 CCID-50 per vial Â
CCID-50 = 50% cell culture infectious dose
The vaccine is recommended to prevent dengue caused by virus serotypes 1, 3, 2, and 4 in individuals aged 9-16 with a confirmed history of past dengue infection in endemic areas
Administered in a 3-dose series, each 0.5 mL subcutaneous dose is given at 6-month intervals
It is crucial to note that the vaccine is not approved for those without a confirmed previous dengue infection
Individuals lacking prior infection may be at an elevated risk of severe dengue if vaccinated and subsequently infected
Confirming prior dengue infection through medical records or serological testing before vaccination is advised
Furthermore, the safety and effectiveness of the vaccine have not been established for individuals from nonendemic areas traveling to regions where dengue is prevalent
See Pediatric Dosing
immunosuppressants may enhance the adverse/toxic effect of dengue Vaccine
immunosuppressants may enhance the adverse/toxic effect of dengue Vaccine
immunosuppressants may enhance the adverse/toxic effect of dengue Vaccine
immunosuppressants may enhance the adverse/toxic effect of dengue Vaccine
immunosuppressants may enhance the adverse/toxic effect of dengue Vaccine
immunosuppressants increase the toxicity of the dengue tetravalent vaccine
immunosuppressants increase the toxicity of the dengue tetravalent vaccine
immunosuppressants increase the toxicity of the dengue tetravalent vaccine
immunosuppressants increase the toxicity of the dengue tetravalent vaccine
immunosuppressants increase the toxicity of the dengue tetravalent vaccine
may have an increased adverse effect when combined with dengue tetravalent vaccine
may have an increased adverse effect when combined with dengue tetravalent vaccine
may have an increased adverse effect when combined with dengue tetravalent vaccine
atoltivimab/maftivimab/odesivimabÂ
The immunosuppressive properties of odesivimab/maftivimab/atoltivimab reduce the effects of the dengue vaccination
may have an increasingly adverse effect when combined with dengue vaccine
may have an increasingly adverse effect when combined with dengue vaccine
may have an increasingly adverse effect when combined with dengue vaccine
may have an increasingly adverse effect when combined with dengue vaccine
may have an increasingly adverse effect when combined with dengue vaccine
dengue vaccine efficacy will be reduced by abrocitinib
when both drugs are combined, there may be an increased risk or severity of infection from the vaccine  
interaction with methotrexate may diminish the therapeutic effects of the vaccine, avoid combination
interaction with trimetrexate may diminish the therapeutic effects of the vaccine, avoid combination
when both drugs are combined, there may be an increased risk of developing an infection from the vaccine   
when both drugs are combined, there may be an increased risk of developing an infection from the vaccine  
interaction with trimetrexate may diminish the therapeutic effects of the vaccine, avoid combination
when both drugs are combined, there may be an increased risk of developing an infection from the vaccine   
when both drugs are combined, there may be an increased risk of developing an infection from the vaccine  
when both drugs are combined, there may be a decreased therapeutic effect of the vaccine  
when both drugs are combined, there may be a decreased therapeutic effect of the vaccine  
it may reduce the therapeutic efficacy of the dengue vaccine
may decrease the effects of each other
may increase the adverse effects of corticosteroids
may increase the toxic effect of immunosuppressants
may increase the toxic effect of immunosuppressants
may increase the toxic effect of immunosuppressants
may increase the adverse effect of Immunosuppressants
may increase the adverse effect of Immunosuppressants
antithymocyte globulin equineÂ
may increase the adverse effect of Immunosuppressants
may increase the toxic effect of Immunosuppressants
dengue vaccine efficacy will be reduced by anifrolumab
dengue vaccine efficacy will be reduced by pharmacodynamic antagonism of cyclosporine
dengue vaccine efficacy will be reduced by ozanimod
dengue vaccine efficacy will be reduced by ponesimod
may increase the adverse/toxic effect of dengue vaccine
may increase the adverse/toxic effect of dengue vaccine
may increase the adverse/toxic effect of dengue vaccine
may increase the adverse/toxic effect of dengue vaccine
may increase the adverse/toxic effect of dengue vaccine
It may diminish the immunosuppressive effects when combined with risankizumab
By immunosuppressive effects, the effect of vaccine activity decreases and results in risk of infection.
By immunosuppressive effects, the both the drugs action either decreases and results in risk of infection.
when dengue vaccine is combined with melphalan the therapeutic efficacy of the vaccine decreases
when both the drugs combine the effect of vaccine decreases by immunosuppressive effects and increase the risk of infection.
 when thiotepa and dengue vaccine combines, thiotepa decreases the effects of the vaccine by immunosuppressive effects     
live vaccines are not recommended, oncological agents may diminish the therapeutic effects of live vaccines
brentuximab vedotin has a reduced impact on the efficacy of the dengue vaccine, caused due to immunosuppression. Risk of infection persists.
may diminish the therapeutic effects of the vaccine
may reduce the immune response to dengue vaccine due to immunosuppressive effects
may diminish immune response to dengue vaccine
the effect of the dengue vaccine is decreased by gemcitabine through immunosuppression/risk of infection
may diminish immune response to dengue vaccine
may diminish immune response to dengue vaccine
the effect of the dengue vaccine is decreased by fluorouracil through immunosuppression/risk of infection
may reduce therapeutic effects of dengue vaccine
when both drugs are combined, there may be an increased risk or severity of infection  
encorafenib, in combination with the dengue vaccine, shows immunosuppression. It decreases the effect of the dengue vaccine
when both drugs are combined, there may be an increased risk of infection Â
when both drugs are combined, there may be an increased risk of infection 
in combination with the dengue vaccine, neratinib decreases its effect by immunosuppression
may diminish the therapeutic effects of the vaccine
dengue vaccine efficacy will be reduced by abatacept by immunosuppression
dengue vaccine efficacy will be reduced by abemaciclib by immunosuppression
dengue vaccine efficacy will be reduced by adalimumab by immunosuppression
dengue vaccine efficacy will be reduced by afatinib by immunosuppression
dengue vaccine efficacy will be reduced by alemtuzumab by immunosuppression
Adverse drug reactions within 7 days Â
Frequency defined Â
Any grade Â
Myalgia (20-29.2%) Â
Asthenia Â
Swelling (1.6-3.5%) Â
Erythema (1.5-4.1%) Â
Malaise (19.3-24.5%) Â
Headache (29.6-39.9%) Â
Pain (22.5-32.4%) Â
Fever Â
Grade 3 Â
AstheniaÂ
Pain Â
Fever Â
Erythema Â
Malaise Â
Headache Â
Myalgia Â
 Â
Â
Pregnancy warnings:    Â
US FDA pregnancy category: N/AÂ
Lactation:Â
Excreted into human milk is UnknownÂ
Pregnancy Categories:      Â
Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first or later trimester.      Â
Category B: No evidence shown of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women      Â
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for a result in humans must take care of potential risks in pregnant women      Â
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.      Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.      Â
Category N: There is no data available for the drug under this categoryÂ
Patient Information Leaflet   Â
Generic Name: dengue vaccine Â
Why do we use dengue vaccine?Â
dengue vaccine is used to protect individuals against dengue fever, a viral disease caused by the dengue virus. Here are some reasons why dengue vaccines are used:
The primary goal of dengue vaccination is to prevent dengue fever, which can range from a mild flu-like illness to severe and potentially life-threatening forms such as dengue hemorrhagic fever and dengue shock syndrome. Vaccination can reduce the risk of developing these severe forms of dengue.
Dengue is a significant public health concern in many parts of the world, particularly in tropical and subtropical regions. By vaccinating individuals at risk, the spread of the dengue virus can be reduced, leading to a decrease in the overall disease burden and the number of cases.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
